NEW YORK (GenomeWeb News) – Genetic Technologies today said that New York has issued a Clinical Laboratory Permit to the firm, allowing GTG to offer its BREVAGen test to residents of the state.
The permit completes the out-of-state licensures needed, and GTG can offer the breast cancer test to all 50 states in the US. GTG received CLIA certification of compliance for its Australian lab in February 2012.
Its wholly owned subsidiary Phenogen Sciences will soon appoint representatives to cover New York, with a particular emphasis on New York City, GTG said.
Earlier this week, the company said it received additional commitments for a private placement to raise A$800,000 and increased the level of underwriting on its current share purchase plan to A$1.8 million.